Recombinant human interleukin-2 not checked

Immatics US, Inc.

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
10 active
13 in total · 12 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Cancer, Solid Tumor
Main trialPhase 1
“The study purpose is to learn about the safety and tolerability of IMA101 alone (Cohort 1) or in combination with atezolizumab (Cohort 2) in patients with advanced solid cancers that express pre-defined Immatics tumor targets.”In the company’s words, NCT02876510 on ClinicalTrials.gov
Other names
Aldesleukin · Proleukin

Other drugs for Cancer

All 2439 drugs for Cancer

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials13

TrialPhaseCompletesWhat it tests
Phase 1Completed 22 Sep 2021 ACTolog in Patients With Solid Cancers
Phase 1/2Authorised not given A phase I/II trial of peri- and postoperative treatment with histamine dihydrocloride and low-dose interleukin-2 in patients with primary resectable pancreatic cancer.
Phase 2Authorised not given A phase II study on adjuvant vaccination with dendritic cells loaded with autologous tumor homogenate in resected stage IV rare cancers: neuroendocrine tumors (NET) and soft tissue sarcoma (STS).
Phase 2Authorised not given Safety and efficacy of low-dose interleukin-2 therapy in chronic inflammatory barrier diseases (IL-2-ID): a single-center, randomized, double-blind and placebo-controlled phase 2 clinical basket trial
Phase 2Authorised not given DFIL2-REP - Study of the clinical and biological response to repeated administration of low-dose interleukin-2 in patients with type 1 diabetes who have retained residual insulin secretion
Phase 1/2Ended not given A two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 in combination with low-dose subcutaneous interleukin-2 in patients with advanced solid tumors (EVICTION-2)
Phase 2Ended not given NK4AML: Infusion of ex vivo-generated allogeneic natural killer cells in combination with subcutaneous IL-2 in patients with acute myeloid leukemia: a phase I/IIa study
Phase 2Authorised not given Vaccination with autologous dendritic cells loaded with autologous tumour homogenate after curative resection for stage IV colorectal cancer: a phase II study (COREVAX-1)
Phase 2Authorised not given Therapeutic evaluation of low-dose IL-2-based immunomodulatory approach in patients with early AD
Phase 1/2Authorised not given A phase I/II study of CAR-expressing Allogenic iPSC derived NK cells for treatment of autoiMmune disease by B cELl depletion - CARAMEL
Phase 1/2Authorised not given OVACURE-2: Adoptive T cell therapy plus low dose IL-2 (IL-2ld) as first line neoadjuvant therapy in patients with stage III/IV ovarian cancer
Phase 2Authorised not given ALaDIN - Use of low doses of interleukin-2 in autism spectrum disorders
Phase 1Authorised not given THERIPEX - A phase I/II open label non-randomized study, monocentric, single-arm, evaluating Safety and Efficacy of induced T-CD4 Treg by LV vector transduction expressing the FoxP3 cDNA in patients with IPEX syndrom
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Recombinant human interleukin-2

Following is part of Solo: you see every change to Recombinant human interleukin-2 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in